Jun 25, 2019
Dr. Greg van
Wyk, CMO and recently appointed CEO, Noxopharm talks about
the Company's current milestones and upcoming news related to its
lead clinical drug candidate, Veyonda, a chemotherapy and radiation
enhancer that is being studied in men with late stage metastatic
prostate cancer and that may have broad applicability in other
cancer types. Greg notes the explosion of mergers and
acquisitions particularly in the oncology space due to increasing
interest in combining one or more molecules in
treatments.
@Noxopharm
#prostatecancer #cancer #chemotherapy #radiation